Orient Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.91 Cr
- Company Age 27 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.15 Cr
- Revenue Growth 23.10%
- Profit Growth 112.25%
- Ebitda 80.37%
- Net Worth 4.93%
- Total Assets -0.85%
About Orient Drugs
Orient Drugs Private Limited (ODPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 14 March 1997 and has a history of 27 years and ten months. Its registered office is in Malappuram, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.91 Cr.
The company has closed loans amounting to ₹1.15 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Naseer Kalappaden, Abdu Avulan, Favas Avulan, and Six other members serve as directors at the Company.
Company Details
-
Location
Malappuram, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231KL1997PTC011301
-
Company No.
011301
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Mar 1997
-
Date of AGM
19 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Orient Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abdu Avulan
|
Managing Director | 14-Mar-1997 | Current |
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Naseer Kalappaden
|
Director | 14-Mar-1997 | Current |
|
Favas Avulan
|
Director | 26-Dec-2013 | Current |
|
Fathima Avulan
|
Director | 04-Mar-2016 | Current |
|
Zubairali Valiyathodi
|
Director | 04-Mar-2016 | Current |
|
Ummer Thekkepath
|
Director | 31-Mar-2001 | Current |
|
Shibibiyya Mecheri
|
Director | 04-Apr-2022 | Current |
Financial Performance of Orient Drugs.
Orient Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.1% increase. The company also saw a substantial improvement in profitability, with a 112.25% increase in profit. The company's net worth moved up by a moderate rise of 4.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orient Drugs?
In 2021, Orient Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Club Ayurveda Private LimitedUmmer Thekkepath is a mutual person
Charges (Loans)
₹0
₹1.15 Cr
Charges Breakdown by Lending Institutions
- South Indian Bank Limited : 0.90 Cr
- The Federal Bank Ltd. : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Oct 2007 | South Indian Bank Limited | ₹9.00 M | Satisfied |
| 02 Aug 2004 | The Federal Bank Ltd. | ₹2.50 M | Satisfied |
How Many Employees Work at Orient Drugs?
Unlock and access historical data on people associated with Orient Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orient Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orient Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
